Table 4 Univariate analysis of the factors affecting IFN α-2b therapeutic efficacy
Responders (n = 8) | Non-responders (n = 16) | χ2/t/U | P values | |
|---|---|---|---|---|
Age (years) (Mean ± SD) | 23.75 ± 5.60 | 25.50 ± 9.45 | -0.48 | 0.64 |
Gender (Male/Female) | 7/1 | 6/10 | – | 0.03 |
Genotype (A/B/C) | 0/6/2 | 1/3/12 | 7.29 | 0.03 |
HBeAg (+/–) | 8/0 | 16/0 | – | – |
HBeAb (+/–) | 0/8 | 0/16 | – | – |
ALT (IU/L) | 251.50 ± 108.03 | 205.19 ± 94.44 | -1.03 | 0.31 |
AST (IU/L) | 106.63 ± 36.92 | 107.19 ± 73.09 | -0.02 | 0.98 |
ALB (g/L) | 37.95 ± 1.48 | 36.49 ± 2.39 | 1.57 | 0.13 |
TBIL (mg/dL) | 24.27 ± 13.63 | 25.62 ± 9.59 | -0.28 | 0.78 |
CHE (U/L) | 6218.50 ± 477.86 | 6677.25 ± 620.29 | -1.83 | 0.08 |
CREA (mg/dL) | 72.11 ± 62.02 | 67.49 ± 9.55 | 0.30 | 0.77 |
INR for PT | 2.20 ± 0.41 | 2.02 ± 0.50 | 0.88 | 0.39 |
HBV DNA level | 15.34 ± 1.29 | 18.09 ± 1.32 | -4.85 | 0.001 |
SOCS-1 | 5.13 ± 1.89 | 15.38 ± 3.65 | -7.40 | 0.001 |
SOCS-3 | 6.75 ± 1.58 | 20.63 ± 3.24 | -11.37 | 0.001 |